<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hyperhidrosis Management Algorithm</title>
    <style>
        /* --- Global Styles & Variables --- */
        :root {
            --primary-color: #007A7A; /* A professional teal */
            --secondary-color: #4A5568; /* Dark gray for text */
            --background-color: #F7FAFC; /* Light gray background */
            --card-bg: #FFFFFF;
            --border-color: #E2E8F0;
            --red-flag-bg: #FFF5F5;
            --red-flag-border: #FC8181;
            --tag-bg: #E6FFFA;
            --tag-color: #234E52;
            --shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
        }

        @import url('https://fonts.googleapis.com/css2?family=Roboto:wght@400;500;700&display=swap');

        body {
            font-family: 'Roboto', sans-serif;
            margin: 0;
            background-color: var(--background-color);
            color: var(--secondary-color);
            line-height: 1.6;
        }

        /* --- Layout --- */
        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 20px;
        }

        header {
            background: linear-gradient(90deg, var(--primary-color), #005f5f);
            color: white;
            padding: 2rem 1.5rem;
            text-align: center;
            border-bottom-left-radius: 15px;
            border-bottom-right-radius: 15px;
            box-shadow: var(--shadow);
            margin-bottom: 2rem;
        }

        header h1 {
            margin: 0;
            font-size: 2.25rem;
            font-weight: 700;
        }

        .card {
            background-color: var(--card-bg);
            border-radius: 12px;
            padding: 1.5rem 2rem;
            margin-bottom: 1.5rem;
            box-shadow: var(--shadow);
            border: 1px solid var(--border-color);
            transition: transform 0.2s ease-in-out;
        }

        .card:hover {
            transform: translateY(-5px);
        }

        section h2 {
            font-size: 1.75rem;
            font-weight: 700;
            color: var(--primary-color);
            border-bottom: 2px solid var(--border-color);
            padding-bottom: 0.5rem;
            margin-top: 0;
            margin-bottom: 1.5rem;
        }
        
        section h3 {
            font-size: 1.25rem;
            font-weight: 500;
            color: #2D3748; /* Slightly darker gray */
            margin-bottom: 1rem;
        }

        /* --- Grid & Columns --- */
        .grid-container {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 1.5rem;
        }

        .grid-column {
            padding: 1rem;
            border-radius: 8px;
            background-color: #F9F9FB;
        }

        /* --- Specific Elements --- */
        ul {
            list-style-type: none;
            padding-left: 0;
        }
        
        ul li {
            position: relative;
            padding-left: 25px;
            margin-bottom: 0.75rem;
        }

        ul li::before {
            content: '✓';
            position: absolute;
            left: 0;
            color: var(--primary-color);
            font-weight: bold;
        }

        .red-flag {
            background-color: var(--red-flag-bg);
            border: 1px solid var(--red-flag-border);
            border-left: 5px solid var(--red-flag-border);
            padding: 1rem 1.5rem;
            border-radius: 8px;
            margin-top: 1.5rem;
            font-weight: 500;
        }
        
        .red-flag strong {
             color: #C53030;
        }
        
        .tag {
            display: inline-block;
            background-color: var(--tag-bg);
            color: var(--tag-color);
            padding: 0.25rem 0.75rem;
            border-radius: 12px;
            font-size: 0.8rem;
            font-weight: 500;
            margin-left: 10px;
        }
        
        .referral-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 1rem;
        }
        
        .referral-table th, .referral-table td {
            padding: 0.75rem 1rem;
            text-align: left;
            border-bottom: 1px solid var(--border-color);
        }
        
        .referral-table th {
            background-color: #F7FAFC;
            font-weight: 500;
        }

        .step {
            margin-top: 1.5rem;
            padding-top: 1.5rem;
            border-top: 1px solid var(--border-color);
        }
        .step:first-child {
            border-top: none;
            padding-top: 0;
        }

        footer {
            text-align: center;
            padding: 1.5rem;
            margin-top: 2rem;
            background-color: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border-color);
            box-shadow: var(--shadow);
            font-size: 1.1rem;
            font-weight: 500;
            color: var(--primary-color);
        }

        /* --- Responsive Design --- */
        @media (max-width: 768px) {
            .grid-container {
                grid-template-columns: 1fr;
            }
            header h1 {
                font-size: 1.75rem;
            }
            .card {
                padding: 1.5rem;
            }
        }
    </style>
</head>
<body>

    <header>
        <h1>Hyperhidrosis Management Algorithm for Primary Care</h1>
    </header>

    <main class="container">

        <!-- Definition & Impact -->
        <section class="card">
            <p><strong>Definition:</strong> A chronic condition of overactive sweat glands that can significantly affect a patient's quality of life, relationships, and work.</p>
        </section>

        <!-- Initial Assessment -->
        <section class="card">
            <h2>1. Initial Assessment: Differentiate Primary vs. Secondary</h2>
            <div class="grid-container">
                <div class="grid-column">
                    <h3>Primary Focal Hyperhidrosis</h3>
                    <ul>
                        <li><strong>Distribution:</strong> Focal (axillae, palms, soles, craniofacial)</li>
                        <li><strong>Onset:</strong> Childhood/Adolescence (&lt;25 years)</li>
                        <li><strong>History:</strong> Family history common (30-50%)</li>
                        <li><strong>Pattern:</strong> Stops during sleep; improves with age</li>
                        <li><strong>Cause:</strong> Idiopathic (overactive thermoregulation)</li>
                    </ul>
                </div>
                <div class="grid-column">
                    <h3>Secondary Hyperhidrosis</h3>
                    <ul>
                        <li><strong>Distribution:</strong> Generalized (whole body)</li>
                        <li><strong>Onset:</strong> Adulthood (&gt;25 years)</li>
                        <li><strong>History:</strong> No typical family history</li>
                        <li><strong>Pattern:</strong> Occurs during sleep (night sweats)</li>
                        <li><strong>Cause:</strong> Underlying condition or medication</li>
                    </ul>
                </div>
            </div>
            <div class="red-flag">
                <strong>RED FLAG:</strong> Night sweats warrant urgent investigation to rule out infection or malignancy.
            </div>
        </section>

        <!-- Diagnostic Pathway -->
        <section class="card">
            <h2>2. Diagnostic & Investigative Pathway</h2>
            <div class="grid-container">
                <div class="grid-column">
                    <h3>If Secondary Hyperhidrosis is Suspected...</h3>
                    <p>Generalized hyperhidrosis <strong>must</strong> be investigated to exclude serious underlying causes.</p>
                    <strong>Baseline Investigations:</strong>
                    <ul>
                        <li>Full blood count (FBC)</li>
                        <li>Urea & Electrolytes (U&Es), LFTs</li>
                        <li>CRP / ESR</li>
                        <li>HbA1c</li>
                        <li>Thyroid function tests (TFTs)</li>
                        <li>Chest X-ray</li>
                    </ul>
                </div>
                <div class="grid-column">
                    <h3>If Primary Focal Hyperhidrosis is Suspected...</h3>
                    <p>No routine investigations are needed if criteria are met.</p>
                    <strong>Diagnostic Criteria:</strong>
                    <p>Focal, visible sweating for ≥ 6 months with no cause AND at least TWO of the following:</p>
                    <ul>
                        <li>Bilateral and relatively symmetrical</li>
                        <li>Impairs daily activities</li>
                        <li>At least one episode per week</li>
                        <li>Onset before age 25</li>
                        <li>Positive family history</li>
                        <li>Stops during sleep</li>
                    </ul>
                </div>
            </div>
        </section>

        <!-- Management -->
        <section class="card">
            <h2>3. Management in Primary Care</h2>
            <div class="step">
                <h3>Step 1: Lifestyle & First-Line Treatment</h3>
                <p><strong>Self-Care Advice:</strong> Advise avoiding triggers, wearing loose natural-fibre clothing, using moisture-wicking socks/insoles, and considering underarm sweat pads.</p>
                <p><strong>First-Line Treatment: Topical Aluminium Chloride 20%</strong></p>
                <ul>
                    <li><strong>Instructions:</strong> Apply nightly to completely dry skin; wash off in the morning.</li>
                    <li><strong>Efficacy:</strong> Up to 80% effective for mild-to-moderate cases.</li>
                    <li><strong>Trial Period:</strong> Advise a <strong>six-week trial</strong>.</li>
                    <li><strong>Side Effects:</strong> If skin irritation occurs, reduce frequency and consider a mild topical steroid.</li>
                </ul>
            </div>
            <div class="step">
                <h3>Step 2: Second-Line Treatment (if first-line fails)</h3>
                <p><strong>Second-Line Treatment: Oral Oxybutynin <span class="tag">Off-label</span></strong></p>
                 <ul>
                    <li><strong>Indication:</strong> NICE-endorsed option when topical treatments are ineffective.</li>
                    <li><strong>Dosing:</strong> Start 2.5mg OD, titrate slowly up to 5mg BD as tolerated.</li>
                    <li><strong>Monitoring:</strong> Watch for anticholinergic side effects (e.g., dry mouth, constipation).</li>
                </ul>
            </div>
        </section>
        
        <!-- Referral Pathway -->
        <section class="card">
            <h2>4. Review & Referral Pathway</h2>
            <table class="referral-table">
                <thead>
                    <tr>
                        <th>If Treatment is...</th>
                        <th>Next Step</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Effective & Tolerated</strong> (Topical or Oral)</td>
                        <td>Continue long-term management in primary care.</td>
                    </tr>
                    <tr>
                        <td><strong>Ineffective or Not Tolerated</strong> (after trials)</td>
                        <td><strong>Refer to a Dermatologist</strong> for specialist management.</td>
                    </tr>
                </tbody>
            </table>
        </section>

        <!-- Specialist Treatments -->
        <section class="card">
            <h2>5. Overview of Specialist Treatments (Secondary Care)</h2>
            <ul>
                <li><strong>Medications:</strong> Higher-strength topicals; other oral agents (e.g., glycopyrronium, propantheline).</li>
                <li><strong>Iontophoresis:</strong> Electric current passed through water (mainly for palms/soles).</li>
                <li><strong>Botulinum Toxin Injections:</strong> Licensed for severe axillary hyperhidrosis; effect lasts 6-9 months.</li>
                <li><strong>Surgical Options:</strong> Sweat gland removal/laser. ETS is reserved for extreme cases due to high risk of compensatory sweating.</li>
            </ul>
        </section>

        <footer>
            <strong>Key Reassurance Point:</strong> Multiple effective treatment options exist, even in severe cases.
        </footer>
    </main>

</body>
</html>